Stockscreener 앱 받기
32.06
2.13%
0.67
시간 외 거래:
32.06
전일 마감가:
$31.39
열려 있는:
$31.56
하루 거래량:
382.23K
Relative Volume:
1.07
시가총액:
$592.47M
수익:
$294.28M
순이익/손실:
$367.02M
주가수익비율:
1.6953
EPS:
18.9115
순현금흐름:
$75.66M
1주 성능:
+7.84%
1개월 성능:
+23.55%
6개월 성능:
+14.05%
1년 성능:
+88.15%
1일 변동 폭
$31.56
$32.24
1주일 범위
$28.78
$32.24
52주 변동 폭
$16.05
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
명칭
Rigel Pharmaceuticals
전화
650-624-1100
주소
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
32.06 | 580.09M | 294.28M | 367.02M | 75.66M | 18.91 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-04-03 | 재개 | Piper Sandler | Neutral |
| 2022-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-08 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 개시 | B. Riley Securities | Neutral |
| 2020-11-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 재개 | JP Morgan | Overweight |
| 2019-03-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 개시 | Citigroup | Buy |
| 2018-05-02 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 재개 | Piper Jaffray | Overweight |
| 2017-12-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 재개 | H.C. Wainwright | Buy |
| 2017-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-31 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 재확인 | Piper Jaffray | Overweight |
| 2016-07-13 | 개시 | H.C. Wainwright | Buy |
| 2016-06-13 | 개시 | Piper Jaffray | Overweight |
| 2016-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 재확인 | Stifel | Buy |
| 2012-11-29 | 개시 | UBS | Neutral |
| 2012-11-06 | 재확인 | Oppenheimer | Outperform |
| 2012-03-26 | 개시 | Canaccord Genuity | Hold |
| 2010-12-10 | 다운그레이드 | MP Advisors | Outperform → Market Perform |
모두보기
Rigel Pharmaceuticals 주식(RIGL)의 최신 뉴스
(RIGL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
RIGL Stock Price, Quote & Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Why Rigel Pharmaceuticals Lost Big in December - AOL.com
Ritholtz Wealth Management Boosts Rigel Pharmaceuticals Holdings - National Today
Why VAALCO Energy, Rigel Pharmaceuticals, and Companhia Siderurgica Nacional Are Today's 3 Best Stoc - Yahoo
Rigel's 2026 Earnings Goal Sets Up Discounted Stock for Potential Clash With Analysts' 82% Price Projections - Bitget
Rigel Pharmaceuticals Was Easy To DismissNow It's Hard To Ignore (Rating Upgrade) - Seeking Alpha
Rigel pharmaceuticals targets $200M-$210M revenue in 2025 with strong Q1 performance - MSN
Rigel Attracts Big Money as Charts Signal Caution - Bitget
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - StreetInsider
Rigel Pharmaceuticals, Inc. (RIGL) stock price, news, quote and history - Yahoo Finance Singapore
Aug Levels: What is the Moat Score of Rigel Pharmaceuticals IncWeekly Market Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Rigel Pharmaceuticals Grants Inducement RSUs to New Hires - National Today
Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Rigel Pharmaceuticals Inc (FRA:RI2) Stock Price & 30 Year Financial Data - GuruFocus
RIGL PE Ratio & Valuation, Is RIGL Overvalued - Intellectia AI
Rigel Pharmaceuticals (RIGL) seeks approval for equity plan share increases at 2026 meeting - Stock Titan
How (RIGL) Movements Inform Risk Allocation Models - Stock Traders Daily
Rigel Pharmaceuticals Balances Breakout Growth With Caution - The Globe and Mail
Why Rigel Pharmaceuticals Shares Tanked - Yahoo
Hennion & Walsh Asset Management Inc. Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Jim Cramer blesses Rigel Pharmaceuticals as a spec as “it’s doing better than people realize” - MSN
Rigel Pharmaceuticals, Inc. (RIGL) Stock Price, News, Quote & History - Yahoo! Finance Canada
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Rigel Pharmaceuticals’ pralsetinib shows efficacy in NSCLC clinical trial - TipRanks
Rigel Pharmaceuticals (RIGL) Reports Promising Results from ARRO - GuruFocus
Rigel announces publication of final ARROW clinical trial data on Gavreto® (pralsetinib) - marketscreener.com
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology - PR Newswire
Rigel Pharmaceuticals Receives 'Moderate Buy' Rating from Analysts - National Today
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Market Review: What is the Moat Score of Rigel Pharmaceuticals Inc2026 Highlights & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Jim Cramer Blesses Rigel Pharmaceuticals as a Spec as “It’s Doing Better Than People Realize” - Insider Monkey
Vanguard realignment leads to 0 shares reported for Rigel (RIGL) - Stock Titan
Jim Cramer Broke Down 16 Stocks Including Pharma Plays for Rising Oil - Insider Monkey
Rigel Pharmaceuticals (RIGL) Q4 earnings miss estimates - MSN
Rigel Pharmaceuticals Q4 2025 earnings preview - MSN
Rigel’s New Olutasidenib Interaction Study Signals Long-Game Strategy for RIGL Investors - TipRanks
Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure - Fierce Biotech
Rigel Pharmaceuticals shows rising relative strength; still shy of key benchmark - MSN
Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy? - MSN
Rigel enrols first subject in R289 Phase Ib expansion for MDS - MSN
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update - Quantisnow
Rigel Pharmaceuticals (RIGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):